TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01107470

Intervention type: DRUG
Intervention: hFSH（Fostimon）
Description: After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).

Intervention type: DRUG
Intervention: hFSH（Fostimon）
Description: After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).

Intervention type: DRUG
Intervention: hFSH（Fostimon）
Description: After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).

Intervention type: DRUG
Intervention: hFSH（Fostimon）
Description: After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
Study: NCT02021591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Diabetes Detective (MoDD)
Description: MoDD is a web-based application that is designed to help individuals with diabetes identify specific problems related to glycemic control, and engage in problem-solving process. MoDD includes a number of messages that explain its users the nature of various problems related to glycemic control, aspects of individuals' behaviors that might have contributed to these problems, and alternative behaviors that could help to improve glycemic control. In addition to these messages displayed on the MoDD website, study participants may receive SMS messages with reminders to test blood glucose, or to follow the selected new behavior.
Study: NCT03218722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-Thrombin Concentrate Complex
Description: Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg PCC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg Saline solution.
Study: NCT01163604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: Intravenous Infusion, 20mg/day for 2 days before and 3 days after stenting, (10mg/3h, twice a day), with accompanied aspirin and clopidogrel treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-argatroban treated group
Description: Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
Study: NCT02573610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-108
Description: Subjects will be assigned to receive DE-108 ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 0.5%
Description: Subjects will be assigned to receive Levofloxacin 0.5% ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
Study: NCT03169491

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous positive airway pressure (CPAP)
Description: CPAP dispositives will be used by the children in the study every night for two weeks. Devices AutoSet Spirit from ResMed.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Description: CPAP dispositives will be used by the children in the study every night for two weeks. Devices AutoSet Spirit from ResMed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: CPAP dispositives will be used by the children in the study every night for two weeks. Devices AutoSet Spirit from ResMed.
Study: NCT02636972

Intervention type: DRUG
Intervention: OCPs
Description: Participants in the contraceptive pill groups can use any one of the following contraceptive pills:~Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra

Intervention type: DRUG
Intervention: OCPs
Description: Participants in the contraceptive pill groups can use any one of the following contraceptive pills:~Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra

Intervention type: DRUG
Intervention: OCPs
Description: Participants in the contraceptive pill groups can use any one of the following contraceptive pills:~Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra

Intervention type: DRUG
Intervention: OCPs
Description: Participants in the contraceptive pill groups can use any one of the following contraceptive pills:~Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra
Study: NCT01280773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA
Description: Neurally adjusted ventilatory assist (NAVA) was delivered by a SVi ventilator. NAVA utilizes EAdi, a reflection of the neural respiratory output to diaphragm, as its primary source to trigger and cycle-off assist in synchrony with neural inspiratory efforts.
Study: NCT02037711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0.5%
Description: Group I (Chirocaine group) (n=20): Levobupivacaine 0.5% will be instilled during insufflations of CO2 at the beginning of surgery at a dose of 2mg/kg.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: Group II (control group) (n=20): laparoscopy done with instillation of normal saline instead of levobupivacain
Study: NCT02191189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine suspension, into Enterion™ capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine suspension, into Enterion™ capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine suspension, into Enterion™ capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine suspension, into Enterion™ capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine suspension
Study: NCT04488705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETD002 - single dose
Description: Single ascending doses of ETD002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - single dose
Description: Single doses of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETD002 - 7 day repeat dose
Description: Twice daily doses of ETD002 for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETD002 - 7 day repeat dose
Description: Twice daily doses of ETD002 for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - 7 day repeat dose
Description: Twice daily doses of Placebo for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - 7 day repeat dose
Description: Twice daily doses of Placebo for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETD002 - 14 day repeat dose
Description: Twice daily doses of ETD002 for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - 14 day repeat dose
Description: Twice daily doses of Placebo for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Twice daily doses of salbutamol for 3 days (Days 5, 6 \& 7)
Study: NCT03191539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: 30 mg twice a day during 52 weeks. In the first 6 days will be a dose escalation
Study: NCT00424372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
Study: NCT02694224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Smo inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (80 mg/m2) weekly x 12 doses followed by sequential dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide (600 mg/m2) each 2 weeks x 4 doses with granulocyte macrophage colony stimulating factors (GM-CSF) support

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (80 mg/m2) weekly x 12 doses followed by sequential dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide (600 mg/m2) each 2 weeks x 4 doses with granulocyte macrophage colony stimulating factors (GM-CSF) support

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide each 2 weeks x 4 doses with GMCSF after Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide each 2 weeks x 4 doses with GMCSF after Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: dose dense Cyclophosphamide (600 mg/m2) together with Epirubicin each 2 weeks x 4 doses with GMCSF after Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: dose dense Cyclophosphamide (600 mg/m2) together with Epirubicin each 2 weeks x 4 doses with GMCSF after Paclitaxel
Study: NCT05121584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of an anterior crown restoration as a final restoration
Description: Placement of an anterior crown restoration as a final restoration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of an anterior crown restoration as a final restoration
Description: Placement of an anterior crown restoration as a final restoration
Study: NCT03587610

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Remedial vaccination
Description: * if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~* if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination.
Study: NCT02836171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate Tablets
Description: apatinib was administered in the morning after an overnight fast of at least 10 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole Capsules
Description: rifampicin was administered in the morning 0.5 hours after breakfast
Study: NCT01280188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin Oral Melt
Description: Oral melt formulation starts on Day 2. The target initial dose of the orally disintegrating tablet is 180µg/day (60µg taken 3 times a day) and adjusted to optimally stabilise the participant's condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin intranasal
Description: Self-administered intranasal desmopressin throughout the pre-study observation period (Days -30 to Day 0) and on study Day 1
Study: NCT00770120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study: NCT01595360

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is applied directly to the bleeding site after tooth extraction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-173
Description: It is applied directly to the bleeding site after tooth extraction
Study: NCT00394966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 619734 Dose 1
Description: SCH 619734 10 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 619734 Dose 2
Description: SCH 619734 25 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 619734 Dose 3
Description: SCH 619734 100 mg (2 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 619734 Dose 4
Description: SCH 619734 200 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
Study: NCT00028028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01631474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-03-01
Description: Topical cream, applied once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical cream, applied once or twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-03-01
Description: Topical cream, applied twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-03-01
Description: Topical cream, applied twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-03-01
Description: Topical cream, applied twice a day
Study: NCT03527212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJP-0035 0.001%
Description: Self-administration of 1 drop (approximately 40 µL) of 0.001% SJP-0035 ophthalmic solution into each eye 4 times daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-administration of 1 drop (approximately 40 µL) of placebo ophthalmic solution into each eye 4 times daily for 4 weeks
Study: NCT01592188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitively-Based Compassion Training (CBCT)
Description: CBCT is a 12 week program that begins by teaching mindfulness and attention. It then goes on to use new mindfulness skills to consider topics of compassion, or unbiased acceptance and compassion for all other people, both friends, unfamiliar people, and enemies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness training
Description: Mindfulness training will consist of 6 weeks training in mindfulness meditation.
Study: NCT02488629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCB01A
Description: This study is a single arm, open-label, Phase II trial
Study: NCT03840278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: Experimental stable glucagon for use in the iLet Bionic Pancreas
Study: NCT03025022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-JNJ-42847922 40 mg
Description: Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 containing maximally 100 MicroCurie as a 40 milliLitre (mL) solution.
Study: NCT01196767

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine (in one arm); catheterization (in both).
Description: Parallel study with two groups:~1. ropivacaine (2 mg.mL-1), at the rate of 4 mL.hr-1 through two subcutaneous catheters lateral to the sternum, both alimented by an elastomeric pump.~2. same protocol, with normal saline instead of ropivacaine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine (in one arm); catheterization (in both).
Description: Parallel study with two groups:~1. ropivacaine (2 mg.mL-1), at the rate of 4 mL.hr-1 through two subcutaneous catheters lateral to the sternum, both alimented by an elastomeric pump.~2. same protocol, with normal saline instead of ropivacaine.
Study: NCT03194048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Chewing Training
Description: FuCT;~* Family training~* Providing optimal sitting posture for children to support oral sensorimotor functions~* Positioning the food to the molar area during every meal to stimulate lateral and rotational tongue movements~* Massage of the upper and lower gums through the front teeth to molar area~* Chewing training to stimulate lateral and rotational tongue movements~* Gradually increasing the food consistency, for 12 weeks in 5 sets (1 set = 20 min) each day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical Oral Motor Exercises
Description: Classical Oral Motor Exercises;~* Family training~* passive and active lip and tongue exercises, for 12 weeks in 5 sets (1 set = 20 min) each day
Study: NCT04985253

Intervention type: OTHER
Intervention: prediction of overall survival using Web based PREDICTV2.0 portal
Description: Predict is an online prognostication and treatment benefit tool developed in the UK, using cancer registration and survival data recorded by the Eastern Cancer Registration and Information Centre (ECRIC) for 5694 women diagnosed in East Anglia from 1999-2003.~The model was validated in a second cohort of 5468 women from the West Midlands Cancer Intelligence Unit and is available online (www.predict.nhs.uk) providing 5-and 10-year survival estimates and treatment benefit predictions. Wong et al, tested the predictive accuracy of PREDICT V1.0 in the southeast Asian population. There were 67% Chinese patients while 13% were Indians. They showed concordance in observed and predicted OS in most subgroups except for women whore less than 40 years of age.
Study: NCT02443376

Intervention type: DEVICE
Intervention: Complior Analyse System
Description: Pulse Wave Velocity PWV and central Pressure analysis

Intervention type: DEVICE
Intervention: Complior Analyse System
Description: Pulse Wave Velocity PWV and central Pressure analysis

Intervention type: DEVICE
Intervention: BCM- Body Composition Monitor
Description: BCM - Body Composition Monitor gives information about:~Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM)
Study: NCT02142452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: Behavioral intervention will include a group class for women in their 3rd trimester followed by a mobile texting program to support behavior change postpartum.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Prenatal Care
Study: NCT02940691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/elbasvir
Description: Grazoprevir/elbasvir (100mg/50mg) once daily for 12 weeks.
Study: NCT02866877

Intervention type: OTHER
Intervention: Pharmacokinetic modeling
Description: Timed blood draws and urine collections to model drug clearance
Study: NCT01440309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: mesenchymal stem cell
Description: Mesenchymal stem cells,5-50 million/kg, Intravenous infusion, One dosage，whether to give another dosage depending on patients' condition
Study: NCT02391714

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IUD insertion
Description: The IUD (Mirena® or ParaGard®) insertion procedure will occur in the usual manner for both arms. A bimanual exam will be performed, the speculum placed and the cervix visualized. The cervix will then by cleaned with iodine solution. If you are allergic to iodine, we will use chlorhexidine instead. A tenaculum will be placed on the cervix and a uterine sound will be used to measure cavity length. The Mirena® or ParaGard® IUD will be inserted with the specific introducer.
Study: NCT01440309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ursodeoxycholic acid
Description: 13-15 mg/kg/day, to the end of the study
Study: NCT01636895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of suphladoxine/pyrimethamine as IPTp
Description: 3 tablets (single dose)given twice during pregnancy one month apart after quickening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of suphladoxine/pyrimethamine as IPTp
Description: 2 courses of 3 tablets of 500 mg N1-(5,6-dimethoxy-4-pyrimidinyl) sulfanilamide (sulfadoxine) and 25 mg 2,4-diamino-5-(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine)administered (at least 1 month apart) as DOTs to pregnant mother after quickening
Study: NCT01800292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: Subjects will be started on sildenafil at 20 mg PO TID at the baseline visit. Each individual will serve as his/her own control. Subjects will be evaluated at 3 months, with participation completed at that time.
Study: NCT03199703

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baylis transseptal system group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard conventional transseptal group
Study: NCT02105077

Intervention type: DRUG
Intervention: Anesthesia with inhalative application of xenon gas